(1)
Calgary, Alberta (Newsfile Corp. - May 7, 2021) - Crestview Exploration Inc. (
CSE: CRS) (FSE: CE7) ( Crestview or the Company ) is pleased to announce the commencement of the phase 1 drilling at the Cimarron gold prospect ( Cimarron or the Property ; see Map 1 below).
MAP 1
https://orders.newsfilecorp.com/files/7042/83254 094e5b0c44d9092d 003full.jpg
The company broke ground on the first of nine planned drill holes for the phase 1 program at Cimarron on Thursday, May 6, 2021. As a reminder to the reader, this phase 1 drill program will be testing a historic resource in the area of the historic San Antonio mine (see Map 2 below). The targeted areas for phase 1 drilling received significant attention in the 1980 s, with an approximately 50,000-ounce shallow oxide gold resource outlined but never extracted (reference is to an internal mining report by Peter Hahn to Budge Mining Ltd. dated February 17, 1987. This resource should be considered as historic and not complian
The company broke ground on the first of nine planned drill holes for the phase 1 program at Cimarron on Thursday, May 6, 2021. As a reminder to the reader, this phase 1 drill program will be testing a historic resource in the area of the historic San Antonio mine (see Map 2 below). The targeted areas for phase 1 drilling received significant attention in the 1980’s, with an approximately 50,000-ounce shallow oxide gold resource outlined but never extracted (reference is to an internal mining report by Peter Hahn to Budge Mining Ltd. dated February 17, 1987. This resource should be considered as “historic” and not compliant with NI 43-101 standards.). The phase 1 drill program is focused on validating and expanding on the historic resource by drilling a selection of twin holes to greater depths than the former operators.
Support a New Drug Application Filing for Simufilam in Alzheimer’s disease - - Agreement Reached to Use ADAS-Cog as Co-Primary Efficacy Endpoint -
- Pivotal Phase 3 Program Remains On-track to be Initiated 2
nd Half 2021 -
AUSTIN, Texas, Feb. 22, 2021 (GLOBE NEWSWIRE) Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s disease. Official EOP2 meeting minutes indicate FDA and Cassava Sciences agree on key elements of a pivotal Phase 3 clinical program in support of a New Drug Application (NDA) filing for simufilam in Alzheimer’s disease. Agreements reached during the EOP2 meeting show a clear path forward for advancing simufilam into Phase 3 studies in the second half of 2021.